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Abstract: Hyperaminoacidemia following ingestion of cows-milk may stimulate muscle anabolism
and attenuate exercise-induced muscle damage (EIMD). However, as dairy-intolerant athletes
do not obtain the reported benefits from milk-based products, A2 milk may offer a suitable
alternative as it lacks the A1-protein. This study aimed to determine the effect of A2 milk on recovery
from a sports-specific muscle damage model. Twenty-one male team sport players were allocated
to three independent groups: A2 milk (n = 7), regular milk (n = 7), and placebo (PLA) (n = 7).
Immediately following muscle-damaging exercise, participants consumed either A2 milk, regular
milk or PLA (500 mL each). Visual analogue scale (muscle soreness), maximal voluntary isometric
contraction (MVIC), countermovement jump (CMJ) and 20-m sprint were measured prior to and 24, 48,
and 72 h post EIMD. At 48 h post-EIMD, CMJ and 20-m sprint recovered quicker in A2 (33.4 ± 6.6
and 3.3 ± 0.1, respectively) and regular milk (33.1± 7.1 and 3.3± 0.3, respectively) vs. PLA (29.2± 3.6
and 3.6 ± 0.3, respectively) (p < 0.05). Relative to baseline, decrements in 48 h CMJ and 20-m sprint
were minimised in A2 (by 7.2 and 5.1%, respectively) and regular milk (by 6.3 and 5.2%, respectively)
vs. PLA. There was a trend for milk treatments to attenuate decrements in MVIC, however statistical
significance was not reached (p = 0.069). Milk treatments had no apparent effect on muscle soreness
(p = 0.152). Following muscle-damaging exercise, ingestion of 500 mL of A2 or regular milk can limit
decrements in dynamic muscle function in male athletes, thus hastening recovery and improving
subsequent performance. The findings propose A2 milk as an ergogenic aid following EIMD, and
may offer an alternative to athletes intolerant to the A1 protein.
Keywords: A2 milk; exercise recovery; muscle damage; team sports; muscle function
1. Introduction
Participation in unaccustomed eccentric exercise often causes exercise-induced muscle damage
(EIMD) [1–3]. Physical activity with a large eccentric component includes resistance training, sprinting
and plyometrics [4], all of which are common amongst sporting activities [5]. The exact causes of
EIMD are ill-understood, but it is thought to be initiated by mechanical disruption of the myofibrils,
which results in ultrastructural damage to the whole muscle cell [6,7]. It has been proposed that muscle
function after EIMD is compromised through damage to the excitation-contraction (EC) coupling
system, which is essential for muscle contraction and force output [8,9]. Mechanical damage coupled
with the disruption of the EC coupling system is thought to activate a cascade of intracellular reactions
such as an influx of calcium (Ca2+) into the cytosol that precipitate an acute phase inflammatory
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response [7]. In conjunction with other biochemical changes, such as increased reactive oxygen species
(ROS) production [10], the inflammatory response might further degrade the muscle architecture
in the days following muscle-damaging exercise [11,12]. Such changes can reduce the ability to
generate power, evoke muscle pain (delayed onset muscle soreness, DOMS) and increase the release
of intramuscular enzymes (i.e., creatine kinase) [6,13,14]. These symptoms generally peak 48 h after
exercise [15] but can persist for 5–7 days [16,17]. This is particularly problematic in team-sports, where
athletes are often required to train and/or compete on multiple occasions during a weekly cycle [18,19].
As a consequence, subsequent exercise performance might be impaired, and the propensity for injury
increased [20].
Examples of the detrimental consequences of EIMD on exercise performance have been well
documented [21]; twelve resistance-trained males demonstrated a 22.5% reduction in vertical jump
height, and a 3-fold increase in muscle soreness after a bout of muscle-damaging drop jumps [22].
In a recent study with team-sports trained players, power generating ability (as measured by counter
movement jump performance and reactive strength index) was reduced for up to 72 h after a single bout
of repeated sprint exercise [1]. Such prolonged impairments in muscle function after muscle-damaging
exercise are likely to negatively affect an athlete’s ability to perform in real-world sporting situations
(i.e., competitions or training) [5,19].
Numerous studies have suggested that protein (PRO)-rich supplements are capable of attenuating
indices of EIMD. The effects of whey PRO [23], casein PRO [24], leucine [25], and branched-chain
amino acids (AA) [22] have been investigated for their ability to attenuate EIMD and hasten recovery,
with many suggesting favourable effects [22–24].
More recently, a combination of PRO-carbohydrate (CHO) beverages such as dairy-milk [26],
which have a favourable digestible and indispensable amino-acid score (DIAAS) > 1.0 [27], have
expedited recovery of muscle function following eccentric-heavy exercise [28]. Dairy milk by mass
contains ~80% casein and ~20% whey PRO, providing an advantageous balance of slow and fast
digesting AA to the muscle for protein turnover [29]. By increasing AA availability, in particular leucine,
milk activates anabolic signalling of mammalian target of rapamycin (mTOR), the key metabolic
regulator for muscle PRO synthesis [30]. Post-exercise feeding of PRO and CHO can also favourably
raise blood insulin levels from ~5 to 30 m/UL [31], providing an ideal insulinogenic environment
which may suppress the breakdown of skeletal muscle via the ubiquitin proteasome pathway [28,32].
This increase in insulin action is attributed to increased microvascular perfusion [33].
In a series of studies [26,34–36] milk supplementation post-eccentric exercise was shown to
attenuate symptoms of EIMD, such as muscle soreness and deficits in muscle function. At present, the
mechanisms underlying reduction in EIMD with milk are unclear. However, one possible mechanistic
explanation is that milk inhibits the activity of calpains and other degradative pathways upregulated
after muscle-damaging exercise [37–39]. This, in turn, preserves the integrity of the muscle cell,
especially the proteins responsible for force generation and transmission. Irrespective of the exact
mechanisms, the above data suggest that milk is a promising recovery intervention after strenuous
exercise [29]. However, for athletes who are intolerant to lactose and/or the A1 beta-casein PRO, found
in regular milk, these ergogenic benefits remain elusive, including: PROs for muscle recovery, CHO
for glycogen resynthesise, and electrolyte and vitamin replacement for re-hydration [40,41].
The general assumption surrounding the milk intolerance syndrome is that it is triggered by
lactose malabsorption [42,43]. However, as described in the 2010 National Institutes of Health
Consensus statement on lactose intolerance, many who suffer from self-reported gastrointestinal
(GI) issues display no evidence of insufficient lactase enzyme activity [44]. An alternative mechanism
supported by growing evidence [45–47] is that bovine beta-cosmorphin-7 (BCM-7) (See Figure 1),
derived from A1-beta casein in regular milk, but not A2-beta casein, expresses opioid receptors in the
human GI tract upon digestion which may cause motility disorders, inflammation, abdominal pain
and loose stools [44,48]. Furthermore, it has been speculated the interaction of lactose and BCM-7 with
regular milk may exacerbate the above-mentioned symptoms [48]. Consequently, an alternative option
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for athletes who suffer from these GI discomforts with regular milk is warranted. A2 milk is a natural,
biologically-occurring form of cow’s milk, identical in nutrient composition to regular milk, but lacks
A1-beta casein and therefore BCM-7 expression, and as such may offer a substitute [49]. However, no
study to date has investigated the effects of A2 milk on EIMD following strenuous exercise.
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Table 1. Group subject characteristics. 
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isometric contraction. No significant differences were detected between groups for any variable (p > 
0.05). 
2.2. Study Design 
Participants were assigned to one of three independent groups, in a double‐blind design. On the 
first day of  the  trial, participants performed a  range of neuromuscular  functional  tests before  the 
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Accordingly, the aim of this study was to examine whether A2 milk is equally as effective as
regular milk for attenuating EIMD, following a sport-specific bout of repeated sprint exercise. Hence,
the authors hypothesised that A2 milk would be as effective as regular milk for attenuating markers of
EIMD. In addition, both milk supplements would be more effective than a placebo.
2. Materials and Methods
2.1. Participants
Twenty-one healthy males, who regularly competed in team-sports (Gaelic football n = 7; soccer
n = 7; rugby n = 7) were recruited to take part in this study (see Table 1). Sample size estimates
were based on previous literature examining milk supplementation and EIMD that had shown a
statistical effect [26,34]. Following institutional ethical approval (W14026049), all laboratory procedures,
associated risks and benefits were illustrated both verbally and in written format, before participants
provided written consent. Participants were familiarised with all laboratory procedures prior to study
commencement and instructed to arrive at th laboratory in a rested state, having avoided strenuous
physical activity for a le st 72 h before testing. Parti ipa ts were also instructed to refrain from
exercise, nutritional supplements (whey PRO, casein PRO, bra ched-chain AA, c eatine), caffeine,
alcohol an an i-inflammatory dr gs for the duration of the study. Pa ticipants w re excluded if they
had recently suffered from a musculoskeletal injury, were receiving prescribed medications or had an
intolerance to dairy or lactose products. To minimise diurnal variation, participants were tested at the
same time each day [50].
Table 1. Group subject characteristics.
Group Baseline MVIC (N·m) Age (Years) Height (m) Weight (kg)
A2 milk 685 89 3 3 178.8 ± .1 79.4 ± 10.1
Regular Milk 644 ± 74 23 ± 1 183.0 ± 8.6 81.4 ± 13.1
Placebo 606 ± 74 22 ± 1 180.7 ± 5.5 77.1 ± 7.8
Values presented as mean ± standard deviations (SD; n = 7 per group). MVIC: maximal voluntary isometric
contraction. No significant differences were detected between groups for any variable (p > 0.05).
2.2. Study Design
Participants were assigned to one of three independent groups, in a double-blind design. On the
first day of the trial, participants performed a range of neuromuscular functional tests before the
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repeated sprint protocol. Immediately after the repeated sprint protocol, participants consumed their
allocated drinks. The dependent variables (visual analogue scale, muscle soreness), countermovement
jump height (CMJ), maximum voluntary isometric contraction (MVIC) and 20-m sprint were measured
in the respective order prior to and 24, 48, and 72 h after the repeated sprint protocol (See Figure 2).
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Figure 2. Experi e t l esi n of study protocol.
2.3. Nutritional Intervention and Dietary Control
Participants were randomly but equally divided according to their baseline MVIC score
ascertained at familiarisation to consume one of three drinks: A2 milk (a2 semi-skimmed milkTM;
The A2 Milk Company, Surrey, UK) n = 7; regular milk (Tesco semi-skimmed milk; Tesco Stores Ltd.,
Cheshunt, UK) n = 7; placebo (MyProtein maltodextrin 50 g mixed with water (MyProtein, Northwich,
Cheshire, UK)) n = 7 (see Table 2). Each drink was prepared in masked bottles by an external staff
member who was not involved in the trial to ensure both the researchers and participants were blinded
from treatments. Participants recorded their food intake for 24 h prior to and for the 4 trial days
through the use of food diaries. Instructions were given at familiarisation on how to correctly weigh
food, me sure liq ids, and fill in the food diaries. Throughout the trial period participa ts were also
instr cted to verbally po t any GI discomforts associated with the ingestion of milk supplements to
the research team.
Table 2. Macronutrient content per 500 mL of supplement. PRO: protein; CHO: carbohydrate.
Group Energy PRO CHO Fat
A2 milk 1005 kJ/235 kcal 18 g 24 g 9 g
Regular milk 1046 kJ/250 kcal 18 g 24 g 9 g
Placebo 920.5 kJ/220 kcal 0 g 50 g 0 g
2.4. Baseline Performance Indices
2.4.1. Visual Analogue Scale (Muscle Soreness)
Participants were required to squat down to an angle equal to 90◦ knee flexion with feet shoulder
width apart and then ret n to the starting positi n. Participants then rated thei perceived level
of muscle soreness by marking a line on a scale between 0 mm (no pain) and 200 mm (unbearably
painful). This was measured and recorded in mm for the pain score. See [1] for further description.
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2.4.2. Countermovement Jump (CMJ)
CMJ was assessed using a light timing system (Optojump, Microgate, Italy). Participants were
instructed to squat down with their hands on their hips throughout and jump vertically. Participants
were reminded that all efforts must be maximal. Three jumps with a 60-s rest in-between were
performed with the peak jump height used for data analysis. See [39] for further description.
2.4.3. Maximal Voluntary Isometric Contraction (MVIC)
MVIC force of the dominant knee extensor was recorded using a strain gauge (MIE Digital
Myometer, MIE Medical Research Ltd., Leeds, UK). The knee joint angle was set before each contraction
at 90◦ using a goniometer to minimise error derived from alteration in muscle length. All participants
completed three isometric MVIC’s of 3-s duration, separated by a 60-s rest period. The peak MVIC
from the three contractions was used for statistical analysis. See [1] for further description.
2.4.4. 20 m Sprint Test
As described elsewhere [39], participants completed three maximal effort 20-m sprints each day
on an indoor running track. Participants completed the sprint from a standing start 20 cm behind the
line. Timing gates (Brower, Draper, UT, USA) were used to record sprint time with the fastest sprint
used for analysis.
2.4.5. Repeated Sprint Protocol
The repeated sprint protocol was based on previous studies [3,51] which successfully utilised
it as a method of inducing muscle damage. A 30-m section of an indoor running track was marked
using cones and timing gates. A further 10-m deceleration zone was marked at the end of the 30-m
section. Participants first completed a warm up consisting of 400 m of self-paced jogging, and a series
of dynamic sprint drills including high knees, heel flicks and walking lunges, which were conducted
over a measured 10-m section of the aforementioned indoor running track. This was followed by
a series of three practice sprints at the participants perceived 60, 80 and 100% of maximum speed.
Following the warm up, participants were given 5 min to prepare themselves for the repeated-sprint
protocol, during which time no static stretching was performed as it has been previously suggested
to impair sprint performance [52]. Participants then completed 15 × 30 m sprints with a 60-s rest
period in-between repetitions and were instructed to stop within the marked 10-m deceleration zone.
Participants were reminded to exert maximal effort during each sprint. Strong verbal encouragement
was given throughout.
2.5. Statistical Analysis
All data are expressed as mean ± standard deviations (SD). Participants food diaries were
analysed for macronutrient content through dietary analysis software (Microdiet v2.5, Downlee
systems Ltd., Salford, UK). Independent groups were analysed using a mixed model analysis of
variance (SPSS Statistics 22, IBM, Chicago, IL, USA), with three group levels (A2 milk vs. regular
milk vs. placebo) and four time levels (baseline, 24 h, 48 h, 72 h) to establish differences between
groups. Mauchly’s test of sphericity was used to check homogeneity of variance for all variables;
where necessary, any violations of the assumption were corrected using the Greenhouse–Geisser
adjustment. Significant effects were followed up using Tukey post hoc analysis. The alpha level for
statistical significance was set at p < 0.05 a priori. To estimate the magnitude of supplements effects,
Cohen’s d effect sizes (ES) were calculated with the magnitude of effects considered: small (0.20–0.49),
medium (0.50–0.79) or large (>0.80).
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3. Results
3.1. Group Allocation
Analysis revealed no difference between groups in MVIC values used for group allocation
(p = 0.79). Dietary analysis indicated there were no differences in energy (p = 0.82), carbohydrate
(p = 0.48), protein (p = 0.44) or fat (p = 0.56) intake between the groups across the five days (p > 0.05;
See Table 3).
Table 3. Mean energy and macronutrient intake for the three supplement groups over the five trial
days (p > 0.05).
Group Energy PRO CHO Fat
A2 milk 11,984 kcal 510 g 1604 g 452 g
Regular milk 11,879 kcal 571 g 1390 g 419 g
Placebo 11,451 kcal 584 g 1403 g 420 g
3.2. Evidence of Muscle Damage
All measures of neuromuscular function (20-m sprint, CMJ height, MVIC, Muscle Soreness)
showed main effects for time (p = 0.022, p ≤ 0.001, p ≤ 0.001, p ≤ 0.001, respectively) indicating the
repeated-sprint protocol induced muscle damage.
3.3. Effects of Nutritional Supplement
3.3.1. The 20-m Sprint
There were no group effects for the 20-m sprint (p = 0.743); however, a group–time interaction
effect was present (p = 0.026). Post-hoc analysis demonstrated group differences at 48 h post EIMD
in A2 milk vs. PLA (p = 0.046; ES = 1.09) and regular milk vs. PLA (p = 0.032; ES = 0.98). At 48 h, 20-m
sprint time recovered quicker in A2 (3.3 ± 0.1) and regular milk (3.3 ± 0.3) vs. PLA (3.6 ± 0.3)
(See Figure 3). Relative to baseline, decrements in 48 h 20-m sprint time were minimised in A2
(by 0.9 ± 3.4%) and regular milk (by 0.8 ± 1.2%) vs. PLA (by 6.0 ± 7.2%).
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3.3.2. CMJ height
A group effect showed that CMJ height appeared to recover quicker in milk treatments vs. PLA
(p = 0.041). Although no group–time interaction effects were present (p = 0.098), large effect sizes
(1.42; 1.29) were again apparent at 48 h post EIMD, whereby CMJ recovered quicker in A2 (33.4 ± 6.6)
and regular milk (33.1 ± 7.1) vs. PLA (29.2 ± 3.6), respectively (See Figure 4). Relative to baseline,
decrements in 48 h CMJ height were minimised in A2 (by 1.6 ± 3.2%) and regular milk (by 2.5 ± 2.6%)
vs. PLA (by 8.8 ± 4.4%).
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3.3.3. Maximal Voluntary Isometric Contraction (MVIC)
No differences between groups (p = 0.151) or interaction effects between time and group (p = 0.069)
were observed for MVIC (See Figure 5).
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3.3.4. Visual Analogue Scale (Muscle Soreness)
No differences between groups (p = 0.490) or interaction effects between time and group (p = 0.152)
were observed for muscle soreness (p > 0.05) (See Figure 6).
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The benefit of A2/regular milk for male athletes corroborates previous research [34] which
revealed similar improvements in muscle function 48 h after exercise, and additional studies examining
the damage response after combined PRO–CHO supplementation [34,39,54–57]. Nevertheless,
the aforementioned milk studies [26,39,54] employed a laboratory-based muscle damage protocol
(i.e., isokinetic dynamometer or repeated drop jumps). To ensure our findings could be more readily
translated to an athletic cohort, we induced muscle damage through a validated repeated sprint
exercise protocol [3], to simulate some of the movements in team-sport competition.
Several potential mechanisms may explain how A2/regular milk favourably attenuated losses in
functional capacity after muscle-damaging exercise. In the present study, hyperaminacidemia following
the digestion of whey/casein in milk may have initiated protein remodelling [29], primarily due to the
presence of leucine [58], and the other DIAA crucial for a sustained anabolic response [59]. In addition,
the synergistic intake of nutrients post-EIMD would conceivably mediate insulin release which may
have suppressed exercise-induced proteolysis by dampening the activation of the ubiquitin proteasome
pathway [29,60]. We propose that providing milk and its constituents during a period of catabolism
preserved the muscle against adverse effects [61]. In turn, this may have protected contractile proteins
responsible for force-generating capacity [39]. Reduced markers of pro-inflammatory cytokines in the
days following EIMD have also been evident with milk supplementation [35,39]. Taken together, these
mechanisms provide a feasible explanation as to how milk facilitated the maintenance of short-term
dynamic muscle power output, as measured by CMJ-height and 20-m sprint performance, 48 h after
exercise. In support, a plethora of research [28,38,62,63] has documented a well-established link
between myofibrillar disruption and muscle functioning. Furthermore, efficacy of milk proteins to
support greater anabolism with combined whey and casein has previously been shown in comparison
to ingesting either isolated protein alone [64]. Interestingly, the benefits of milk on EIMD were not
apparent until 48 h after exercise. This may be related to PRO degradation rates not increasing until 24 h
after exercise [38]. Various muscle biopsy studies [65–67] have shown the symptoms of ultrastructural
damage become progressively worse post-exercise, peaking at 48 h, and due to slow repair rate subside
within 5–7 days [16,17].
Although milk treatments did not significantly attenuate losses of MVIC, there was a slight
reduction at 48 h which supports existing data [22]. A possible explanation for the non-significance
may be related to the differences in muscle actions during certain performance measures. For instance,
assessing force production through CMJ-height and 20-m sprint speed involves eccentric-concentric
muscle actions. In comparison, MVIC is measured through isometric strength production with no
change in muscle length [53]. Similar reductions in loss of short-term isotonic power output following
EIMD have been observed with beetroot juice ingestion, with no further beneficial effect on isometric
strength [1,68]. Likewise, a single treatment of either cows or goats chocolate milk revealed no benefit
in 2-h post-resistance exercise isometric strength assessed through mid-thigh pull performance [69].
Thus, perhaps a dynamic movement involving the stretch-shortening cycle is required to fully elucidate
milk’s ability to attenuate EIMD, rather than a non-lengthening muscle contraction. Alternatively,
the leucine dosage of ~1.7 g in the present study may have been suboptimal to maximise muscle
protein synthesis, accounting for the non-significance. We cannot rule out this possibility considering
the leucine threshold to maximise muscle remodelling post-exercise in young healthy athletes is
recommended as ~2–3 g [53,70]. However, considering the positive effects milk treatments had on
CMJ-height and 20-m sprint speed, this is difficult to conceive.
In line with previous research [22,35,71], muscle soreness peaked 48 h post-exercise in the present
study. However, supplementation with A2 or regular milk had no beneficial effect on attenuating
soreness, in contrast to other studies [35,39,72] which found soreness was reduced with milk in males.
Interpreting this finding is difficult as the exact mechanism responsible for DOMS is still unknown [72].
It has been suggested the cause is due to damage to the endomysium surrounding muscle fascicles that
occurs following the biphasic assault of exercise. In turn, this may result in nerve ending potentiation
which has shown to correlate with increased muscle soreness [14,39]. However, milk’s effects on
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this mechanism is yet to be elucidated. We postulate the milk dosages administered in the present
study (~18 g PRO in 500 mL), which is slightly less than that reported in [35,72], might have been
inadequate to maximise the post-exercise PRO metabolism response [70,73] associated with perceptions
of soreness.
There are some limitations in this study that need to be acknowledged. Firstly, no muscle biopsy
or inflammatory blood marker was obtained to measure the mechanisms related to muscle damage
and therefore we cannot directly infer how milk treatment enhanced recovery. Secondly, it is unclear
if individuals who are indeed A1-protein intolerant will display the same recovery benefits with
A2-milk following EIMD, as all participants reported no milk allergies prior to trial commencement.
Future trials should consider these aspects and include direct measures of GI symptoms.
5. Conclusions
The primary implication from our study supports the use of A2 milk for athlete recovery in sports
nutrition settings. We found the consumption of 500 mL of A2 or regular milk following repeated
sprint exercise can limit decrements in muscle function in male team-sports athletes, thus hastening
recovery. From a practical perspective, these findings suggest that A2 milk might offer an alternative
to athletes who experience GI issues with regular milk [45]. However, this possibility needs to be
investigated in athletes who are A1 beta-casein intolerant.
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